title: Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy.
abstract: Aberrant O-glycosylation in the hinge region of serum IgA is suggested to be involved in the pathogenesis of IgA nephropathy (IgAN), because the hypoglycosylation including N-acetylneuraminic acid or galactose has been reported in the mucin-type O-glycan of the hinge portion (HP) of IgA deposited in the IgAN patients' kidney. These aberrant glycosylation has been assessed in most of the previous reports by qualitative but not quantitative methods. In the present study, the molar ratios of GalNAc or Gal to HP were analyzed for serum IgA from IgAN patients. The GalNAc/HP ratio was increased in the patients who achieved remission after a combination therapy of tonsillectomy and intravenous corticosteroid, suggesting any non-innate factors to affect the IgA O-glycosylation in IgAN that is thought to be inherently determined. Furthermore, the O-glycosylation status was different among three groups: IgAN patients in the pretreatment stage, IgAN patients in the remission stage after treatment and healthy controls. These results indicated that aberrant O-glycosylation of serum IgA in the IgAN patients would be inherently present and, to some extent, affected by therapeutic intervention. Finally, the quantitative change of O-glycan composition is a novel marker of therapeutic response of IgAN.
authors.affiliation: Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Japan. hiro@kid.med.osaka-u.ac.jp
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Iwatani
authors.forename: Takahiro
authors.initials: T
authors.lastname: Inoue
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Wada
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Nagasawa
authors.forename: Ryohei
authors.initials: R
authors.lastname: Yamamoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Iijima
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Takehara
authors.forename: Enyu
authors.initials: E
authors.lastname: Imai
authors.forename: Hiromi
authors.initials: H
authors.lastname: Rakugi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Isaka
mesh_terms: D000116:Acetylgalactosamine / Q000032:analysis; D061605:Administration, Intravenous; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D015415:Biomarkers / Q000097:blood / Q000737:chemistry; D005260:Female; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000601:surgery / Q000628:therapy*; D006031:Glycosylation; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000737:chemistry*; D008297:Male; D011134:Polysaccharides / Q000032:analysis; D014068:Tonsillectomy; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D007070:Immunoglobulin A; D011134:Polysaccharides; C042441:glycosylated IgA; D000116:Acetylgalactosamine